Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 004720316 approvals41 trials

PharmGen Science, Inc.

Official website

Founded in 1966, KOSPI-listed PharmGen Science makes GI and cardiovascular prescription drugs plus health foods and beauty products.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1966 and listed on the KOSPI in 1990, PharmGen Science is a pharmaceutical and CDMO company. Key products include reflux esophagitis drug 에소맥스정, GI drug 아르시딘에프정, hypertension drugs 바르디핀정/텔로디핀정, hyperlipidemia drugs 리바틴정/크바스틴정/크바젯정, and antithrombotics 우리빅스정/우리몬정. Segments: pharma, healthcare, other; 2025 revenue KRW 146.7bn pharma, KRW 6.5bn healthcare.

Products & technology

  • 에소맥스정
  • 아르시딘에프정
  • 바르디핀정
  • 리바틴정
  • 크바스틴정
  • 본비스정/주
  • 우리빅스정
  • 우리몬정
  • 루카스트정,츄정
  • 마이코졸캡슐
  • 텔로디핀정
  • 크바젯정

Regulatory approvals

data.go.kr

311 Korean MFDS drug approvals · 1989–2026 / 5 Korean MFDS device approvals · 2014–2020

  • MFDS drugAlpezil Duo Tab. 10/20mg2026-07-15
    Drug · Prescription · Approval202602045
  • MFDS drugS-CANDE TABLET 8/2.5mg2026-02-26
    Drug · Prescription · Approval202600578
  • MFDS drugS-CANDE TABLET 16/2.5mg2026-02-26
    Drug · Prescription · Approval202600579
  • MFDS drugS-CANDE TABLET 16/5mg2026-02-26
    Drug · Prescription · Approval202600580
  • MFDS drugTAVAFENO SR Tab.2026-02-26
    Drug · Prescription · Approval202600585
  • MFDS drugEVERCAL D FORTE Tab.2025-09-04
    Drug · OTC · Notification202502332
  • MFDS drugMIGLIS Tab. (Miglitol)2025-07-25
    Drug · Prescription · Approval202501906
  • MFDS drugMipide SR Tab. 150mg2025-05-28
    Drug · Prescription · Approval202501328
  • MFDS drugDeferamin Tab.2025-05-07
    Drug · OTC · Notification202501101
  • MFDS drugEVERCAL D PLUS Tab.2025-03-31
    Drug · OTC · Notification202500733
  • MFDS drugGinkgoPharm Tab.240mg(Ginkgo Leaf Dried Extract)2024-11-15
    Drug · OTC · Notification202402701
  • MFDS drugOnycure topical solution (Efinaconazole)2024-08-19
    Drug · Prescription · Approval202401998
Show 68 more
  • MFDS drugNALIJENTADUO XR Tab. 2.5/1000mg2024-03-22
    Drug · Prescription · Approval202400606
  • MFDS drugNALIJENTADUO XR Tab. 5/1000mg2024-03-22
    Drug · Prescription · Approval202400607
  • MFDS drugEmplozin Duo Tab. 12.5/500mg2023-09-01
    Drug · Prescription · Approval202302608
  • MFDS drugEmplozin Duo Tab. 12.5/850mg2023-09-01
    Drug · Prescription · Approval202302609
  • MFDS drugEmplozin Duo Tab. 12.5/1000mg2023-09-01
    Drug · Prescription · Approval202302610
  • MFDS drugDuojoin Tab.2023-08-10
    Drug · Prescription · Approval202302399
  • MFDS drugDaflozinduo XR tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301898
  • MFDS drugRoxarex SR Tab. 75mg2023-05-24
    Drug · Prescription · Approval202301663
  • MFDS drugJANUATIN Duo Tab. 50/1000mg2023-03-13
    Drug · Prescription · Approval202300842
  • MFDS drugJANUATIN Duo Tab. 50/850mg2023-03-13
    Drug · Prescription · Approval202300843
  • MFDS drugJANUATIN Duo Tab. 50/500mg2023-03-13
    Drug · Prescription · Approval202300844
  • MFDS drugJANUATIN Duo XR Tab. 100/1000mg2023-02-17
    Drug · Prescription · Approval202300609
  • MFDS drugJANUATIN Duo XR Tab. 50/1000mg2023-02-17
    Drug · Prescription · Approval202300610
  • MFDS drugJANUATIN Duo XR Tab. 50/500mg2023-02-17
    Drug · Prescription · Approval202300611
  • MFDS drugDaflozinduo XR tab. 10/1000mg2023-01-06
    Drug · Prescription · Approval202300149
  • MFDS drugEVERCAL D Tab.2022-12-22
    Drug · OTC · Notification202204612
  • MFDS drugVelaBM Tab.2022-07-20
    Drug · Prescription · Approval202203099
  • MFDS drugNALIJENTADUOTABLET2.5/850MILLIGRAM2022-05-03
    Drug · Prescription · Approval202201809
  • MFDS drugNALIJENTADUOTABLET2.5/500MILLIGRAM2022-05-03
    Drug · Prescription · Approval202201810
  • MFDS drugNALIJENTADUOTABLET2.5/1000MILLIGRAM2022-05-03
    Drug · Prescription · Approval202201811
  • MFDS drugEMPLOZIN DUO tab. 5/1000mg2022-04-04
    Drug · Prescription · Approval202201345
  • MFDS drugEMPLOZIN DUO tab. 5/500mg2022-04-04
    Drug · Prescription · Approval202201346
  • MFDS drugEMPLOZIN DUO tab. 5/850mg2022-04-04
    Drug · Prescription · Approval202201347
  • MFDS drugTERALIPTIN DUO SR Tab. 20/1000mg2022-04-04
    Drug · Prescription · Approval202201426
  • MFDS drugTERALIPTIN DUO SR Tab. 10/750mg2022-04-04
    Drug · Prescription · Approval202201427
  • MFDS drugTERALIPTIN DUO SR Tab. 10/500mg2022-04-04
    Drug · Prescription · Approval202201428
  • MFDS drugcenline Tab.2022-02-04
    Drug · OTC · Notification202200555
  • MFDS drugJANUDAJIN Tab. 10/100mg2022-01-04
    Drug · Prescription · Approval202200056
  • MFDS drugRejucell Cream 10.56%2021-10-12
    Drug · OTC · Approval202106878
  • MFDS drugESOMAXDUO tab 20/800mg2021-06-18
    Drug · Prescription · Approval202104740
  • MFDS drugONCEBONE Inj. 5mg/100ml2021-03-26
    Drug · Prescription · Approval202102685
  • MFDS drugJANUATIN Tab. 100mg2021-03-19
    Drug · Prescription · Approval202102456
  • MFDS drugJANUATIN Tab. 50mg2021-03-19
    Drug · Prescription · Approval202102457
  • MFDS drugJANUATIN Tab. 25mgRevoked2021-03-19
    Drug · Prescription · Approval202102458
  • MFDS drugViliptin Tab. 50mgRevoked2021-03-10
    Drug · Prescription · Approval202102216
  • MFDS drugEMPLOZIN tab. 10mg(Empagliflozin)2021-03-05
    Drug · Prescription · Approval202102045
  • MFDS drugEMPLOZIN tab. 25mg(Empagliflozin)2021-03-05
    Drug · Prescription · Approval202102046
  • MFDS drugTERALIPTIN Tab. 20MG2021-01-19
    Drug · Prescription · Approval202100536
  • MFDS drugLIVAZET Tablet 10/10mg2021-01-08
    Drug · Prescription · Approval202100198
  • MFDS drugLIVAZET Tablet 10/20mg2021-01-08
    Drug · Prescription · Approval202100199
  • MFDS drugLIVAZET Tablet 10/40mgRevoked2021-01-08
    Drug · Prescription · Approval202100200
  • MFDS drugWOORIDUL TOFACITINIB Tablet 5mgRevoked2021-01-07
    Drug · Prescription · Approval202100146
  • MFDS drugPARIBM Inj.2020-12-17
    Drug · Prescription · Approval202008964
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-12-14
    Product approval · Class 3체외 제허 20-1087 호
  • MFDS drugANODEX GOLD Tab.2020-11-13
    Drug · OTC · Notification202007844
  • MFDS drugRejucell Plus Cream2020-11-13
    Drug · Prescription · Notification202007865
  • MFDS drugNAMOTAN Inj. 50mgRevoked2020-11-05
    Drug · Prescription · Approval202007586
  • MFDS drugPharmgen INOSIPLEX SYRUPRevoked2020-09-22
    Drug · Prescription · Notification202006520
  • MFDS drugRejucell Cream2020-09-14
    Drug · OTC · Notification202006338
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-08-14
    Product approval · Class 3체외 제허 20-663 호
  • MFDS drugCINABM Tab. 25mg2020-08-14
    Drug · Prescription · Approval202005828
  • MFDS drugPharmgen DIOSMIN Cap.Revoked2020-08-03
    Drug · OTC · Notification202005596
  • MFDS drugPharmgen DIOSMIN Tab.Revoked2020-08-03
    Drug · OTC · Notification202005597
  • MFDS drugTelrock Tab. 80/5mgRevoked2020-07-29
    Drug · Prescription · Approval202005511
  • MFDS drugTelrock Tab. 80/20mgRevoked2020-07-29
    Drug · Prescription · Approval202005512
  • MFDS drugTelrock Tab. 80/10mgRevoked2020-07-29
    Drug · Prescription · Approval202005513
  • MFDS drugTelrock Tab. 40/5mgRevoked2020-07-29
    Drug · Prescription · Approval202005514
  • MFDS drugTelrock Tab. 40/20mgRevoked2020-07-29
    Drug · Prescription · Approval202005515
  • MFDS drugTelrock Tab. 40/10mgRevoked2020-07-29
    Drug · Prescription · Approval202005516
  • MFDS drugDaflozin Tab. 10mg2020-07-23
    Drug · Prescription · Approval202005376
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-07-20
    Product approval · Class 3체외 제허 20-584 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-07-20
    Product approval · Class 3체외 제허 20-583 호
  • MFDS drugCoughSol PLUS SyrupRevoked2020-07-01
    Drug · OTC · Notification202004803
  • MFDS drugNalijenta Tab. 5mg2020-06-29
    Drug · Prescription · Approval202004750
  • MFDS drugSaero Dex Tab. 100mg2020-06-22
    Drug · OTC · Notification202004532
  • MFDS drugCVAZET Tab. 10/10mg2020-05-29
    Drug · Prescription · Approval202004132
  • MFDS drugCVAZET Tab. 10/5mg2020-05-29
    Drug · Prescription · Approval202004133
  • MFDS drugCVAZET Tab. 10/20mg2020-05-29
    Drug · Prescription · Approval202004134

Showing the 80 most recent of 316 records.

Clinical trials

data.go.kr

41 MFDS clinical trial authorisations · 2015–2025 (Bioequivalence 41)

  • BioequivalenceRD-5206-T2025-10-29

    2 trial sites

  • BioequivalenceRD3202-T2025-03-21

    1 trial site

  • BioequivalenceRD3205-T2024-02-06

    2 trial sites

  • Bioequivalence세틴잘정5밀리그램(레보세티리진염산염)2023-12-28

    2 trial sites

  • Bioequivalence미피드서방정150밀리그램(레바미피드)2023-12-01

    1 trial site

  • Bioequivalence테고맥스정50밀리그램(테고프라잔)2023-09-18

    1 trial site

  • Bioequivalence페티노정(펜디메트라진타르타르산염)2023-06-01

    1 trial site

  • Bioequivalence로페트정(펜터민염산염)2023-05-11

    2 trial sites

  • Bioequivalence미피드서방정150밀리그램(레바미피드)2023-03-24

    1 trial site

  • BioequivalenceRD1103-T2023-02-28

    2 trial sites

  • Bioequivalence모사틴정(모사프리드시트르산염수화물)2022-03-17

    2 trial sites

  • Bioequivalence에스디핀정(에스암로디핀베실산염이수화물)2022-01-25

    2 trial sites

Show 29 more
  • Bioequivalence라푸린정10밀리그램(라푸티딘)2022-01-18

    2 trial sites

  • Bioequivalence쎌레코캡슐(세레콕시브)2021-11-17

    2 trial sites

  • Bioequivalence티지제로서방정(페노피브레이트콜린)2021-11-09

    2 trial sites

  • Bioequivalence티지제로서방정(페노피브레이트콜린)2021-11-08

    2 trial sites

  • Bioequivalence파독심정(세프포독심프록세틸)2021-10-29

    2 trial sites

  • Bioequivalence팜피스정(팜시클로비르)2021-10-19

    2 trial sites

  • Bioequivalence모사틴정(모사프리드시트르산염수화물)2021-10-18

    2 trial sites

  • Bioequivalence마이코졸캡슐(플루코나졸)2021-10-07

    2 trial sites

  • Bioequivalence펜클리어맥스정2021-10-06

    2 trial sites

  • Bioequivalence루카스트정 10 밀리그램 (몬테루카스트나트륨)2021-09-13

    2 trial sites

  • Bioequivalence우리들세파클러캡슐250mg(수출명:수클러캡슐250mg,파시클러캡슐250mg)2021-08-23

    2 trial sites

  • Bioequivalence우리빅스정(클로피도그렐황산염)2021-07-29

    2 trial sites

  • Bioequivalence크바젯정10/20밀리그램2021-07-14

    2 trial sites

  • Bioequivalence아스로펜정(아세클로페낙)2021-07-02

    2 trial sites

  • Bioequivalence타바스타정2밀리그램(피타바스타틴칼슘)2021-06-25

    2 trial sites

  • Bioequivalence바르반플러스정160/12.5밀리그램2021-06-09

    2 trial sites

  • Bioequivalence텔로디핀정80/5밀리그램2021-05-07

    2 trial sites

  • Bioequivalence바르반정160mg(발사르탄)2021-02-23

    2 trial sites

  • Bioequivalence덱시부정400mg(덱시부프로펜디.씨)2020-07-09

    2 trial sites

  • Bioequivalence에소맥스정40mg(에스오메프라졸마그네슘삼수화물)2020-05-15

    1 trial site

  • Bioequivalence우리빅스정(클로피도그렐황산염)2020-01-09

    2 trial sites

  • Bioequivalence리바젯정10/20밀리그램2019-09-20

    2 trial sites

  • Bioequivalence바르디핀정10/160밀리그램2019-03-28

    2 trial sites

  • Bioequivalence뉴로스캡슐(가바펜틴)2017-02-27

    2 trial sites

  • Bioequivalence바르디핀정10/160밀리그램2017-01-18

    2 trial sites

  • Bioequivalence알레온정(베포타스틴베실산염)2016-10-12

    2 trial sites

  • Bioequivalence프렐린캡슐150밀리그램(프레가발린)2016-10-11

    2 trial sites

  • Bioequivalence크바스틴정20밀리그램(로수바스타틴칼슘)2016-07-28

    2 trial sites

  • Bioequivalence리바틴정20밀리그램(아토르바스타틴칼슘삼수화물)2015-06-30

    2 trial sites

Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

CALTH. Inc3 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

GC Medical Science Corporation3 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

HUMASIS CO., LTD.3 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

LabGenomics. Co., Ltd.3 shared

KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.

NanoenTek,Inc.3 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

OSANG HEALTHCARE CO.,LTD.3 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

PROTIA INC.3 shared

KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.

SD BIOSENSOR INC.3 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

Sugentech, Inc.3 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

GENEMATRIX INC.2 shared

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

iNtRON Biotechnology, Inc.2 shared

Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.

RollingStone Co., Ltd.2 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition